Your browser doesn't support javascript.
loading
A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer.
Vahabzadeh, Gelareh; Khalighfard, Solmaz; Alizadeh, Ali Mohammad; Yaghobinejad, Mahsa; Mardani, Mahta; Rastegar, Tayebeh; Barati, Mahmood; Roudbaraki, Morad; Esmati, Ebrahim; Babaei, Mohammad; Kazemian, Ali.
Afiliação
  • Vahabzadeh G; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Khalighfard S; Research Center on Developing Advanced Technologies, Tehran, Iran.
  • Alizadeh AM; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Yaghobinejad M; Department of Anatomy, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
  • Mardani M; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Rastegar T; Department of Anatomy, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
  • Barati M; Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Roudbaraki M; Laboratory of Cell Physiology, Inserm U1003, University of Lille, Villeneuve d'Ascq, France.
  • Esmati E; Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Babaei M; Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kazemian A; Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Front Oncol ; 13: 1142275, 2023.
Article em En | MEDLINE | ID: mdl-37251950
ABSTRACT

Introduction:

The present study aimed to investigate the interaction of the common lncRNA-miRNA-mRNA network involved in signaling pathways in different stages of prostate cancer (PCa) by using bioinformatics and experimental methods.

Methods:

Seventy subjects included sixty PCa patients in Local, Locally Advanced, Biochemical Relapse, Metastatic, and Benign stages, and ten healthy subjects were entered into the current study. The mRNAs with significant expression differences were first found using the GEO database. The candidate hub genes were then identified by analyzing Cytohubba and MCODE software. Cytoscape, GO Term, and KEGG software determined hub genes and critical pathways. The expression of candidate lncRNAs, miRNAs, and mRNAs was then assessed using Real-Time PCR and ELISA techniques.

Results:

4 lncRNAs, 5 miRNAs, and 15 common target genes were detected in PCa patients compared with the healthy group. Unlike the tumor suppressors, the expression levels of common onco-lncRNAs, oncomiRNAs, and oncogenes showed a considerable increase in patients with advanced stages; Biochemical Relapse and Metastatic, in comparison to the primary stages; Local and Locally Advanced. Additionally, their expression levels significantly increased with a higher Gleason score than a lower one.

Conclusion:

Identifying a common lncRNA-miRNA-mRNA network associated with prostate cancer may be clinically valuable as potential predictive biomarkers. They can also serve as novel therapeutic targets for PCa patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article